Enliven Therapeutics (ELVN) vs MBX Biosciences (MBX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
MBX Biosciences (MBX) has outperformed Enliven Therapeutics (ELVN) over the past year, gaining 235.8% versus a gain of 105.7%. Enliven Therapeutics is the larger company by market cap ($2.98 billion vs $2.56 billion), about 1.2 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ELVN | MBX |
|---|---|---|
| Share price | $40.63 | $53.25 |
| Market cap | $2.98B | $2.56B |
| 1-day change | -1.76% | -2.37% |
| YTD return | +168.57% | +68.83% |
| 1-year return | +105.67% | +235.75% |
| 5-year return | +182.51% | — |
| EPS (TTM) | $-1.67 | $-2.37 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Net income (latest FY) | $-103.69M | $-87.00M |
| 52-week high | $62.32 | $72.64 |
| 52-week low | $14.79 | $12.94 |
| Distance from 52-week high | -34.80% | -26.69% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +81.32% | +77.09% |
| Average volume | 1.12M | 539.34K |
| Shares outstanding | 73.27M | 48.16M |
| Employees | 67 | 63 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- MBX has outperformed ELVN by 130.1 percentage points over the past year.
About Enliven Therapeutics
ELVN stock →Enliven Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. Its clinical programs comprise ELVN-001, a small molecule kinase inhibitor which is in Phase 1 clinical trial to treat adults with chronic myeloid leukemia; and ELVN-002, a central nervous system (CNS) penetrant and irreversible human epidermal growth factor receptor 2 inhibitor that is in Phase 1 clinical trial for the treatment of non-small cell lung cancer (NSCLC) and other HER2 mutant tumors.
Health Care · Biotechnology: Pharmaceutical Preparations · 67 employees
About MBX Biosciences
MBX stock →MBX Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of precision peptide therapies for the treatment of endocrine and metabolic disorders. Its lead product candidate is Canvuparatide (MBX 2109), a parathyroid hormone peptide prodrug, which is in Phase 3 clinical trial for the treatment of chronic hypoparathyroidism.
Health Care · Biotechnology: Pharmaceutical Preparations · 63 employees
ELVN vs MBX FAQ
Which is bigger, Enliven Therapeutics or MBX Biosciences?
Enliven Therapeutics (ELVN) is larger, with a market capitalization of $2.98B compared with $2.56B for MBX Biosciences (MBX).
Which stock has performed better over the past year, ELVN or MBX?
MBX returned +235.75% over the past 12 months, compared with +105.67% for ELVN (price return, excluding dividends). Past performance does not predict future results.
Are Enliven Therapeutics and MBX Biosciences in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.